Document is current
Any future updates will be listed below
-
Authors
Yoritaka, Asako https://orcid.org/0000-0001-5538-8493
Kobayashi, Yasuko
Hayashi, Tetsuo
Saiki, Shinji
Hattori, Nobutaka
- License Information
-
More Information
Article History
Received: 21 May 2021
Accepted: 17 July 2021
First Online: 28 July 2021
Declarations
:
: The study was approved by the ethics committee of our institution (Koshigaya 30–5).
: Informed consent was obtained from all individual participants included in the study.
: A. Yoritaka and S. Saiki received lecture fees from Takeda Pharmaceutical Co., Ltd., Eisai Pharmaceutical, Co., Ltd., and Ono Pharmaceutical Co., Ltd. N. Hattori was an advisory member of Dai-Nippon Sumitomo Pharma Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Biogen Idec Japan Ltd.; received lecture fees from Dai-Nippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., FP Pharmaceutical Corporation, Eisai Co., Ltd., Novartis Pharma K.K., and AbbVie; and received departmental endowments by commercial entities from Kyowa Kirin Co., Ltd., Nippon Boehringer Ingelheim, Co., Ltd., AbbVie GK, FP Pharmaceutical Corporation, Otsuka Pharmaceutical, Co., Ltd., Dai-Nippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Nihon Medi-physics Co., Ltd., Asahi Kasei Medical Co., Ltd., Ono Pharmaceutical Co., Ltd., MiZ Co., Ltd., AbbVie GK, OHARA Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Boston Scientific Corporation, and Medtronic Inc. All other authors declare no competing interests.
